Market closed
MannKind/$MNKD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
$MNKD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
405
Website
MannKind Metrics
BasicAdvanced
$1.4B
47.40
$0.10
1.26
-
Price and volume
Market cap
$1.4B
Beta
1.26
52-week high
$7.39
52-week low
$4.11
Average daily volume
2M
Financial strength
Current ratio
3.279
Quick ratio
2.938
Long term debt to equity
-179.625
Total debt to equity
-195.465
Interest coverage (TTM)
1.81%
Management effectiveness
Return on assets (TTM)
9.88%
Return on equity (TTM)
-16.98%
Valuation
Price to earnings (TTM)
47.4
Price to revenue (TTM)
4.556
Price to book
-18.22
Price to tangible book (TTM)
-16.7
Price to free cash flow (TTM)
39.635
Growth
Revenue change (TTM)
43.50%
Earnings per share change (TTM)
-323.67%
3-year revenue growth (CAGR)
55.84%
3-year earnings per share growth (CAGR)
-32.47%
What the Analysts think about MannKind
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
MannKind Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MannKind Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MannKind News
AllArticlesVideos
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
GlobeNewsWire·3 weeks ago
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
GlobeNewsWire·2 months ago
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.4B as of April 27, 2025.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 47.4 as of April 27, 2025.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.